Editorial
doi: 10.1136/bmj.m1584.
SGLT2 inhibitors and kidney outcomes in the real world
Affiliations
- PMID: 32349997
- DOI: 10.1136/bmj.m1584
Item in Clipboard
Editorial
SGLT2 inhibitors and kidney outcomes in the real world
BMJ.
.
No abstract available
Conflict of interest statement
Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The author declares the following other interests: research funding received from the National Institutes of Health (US) and service on the Board of Directors for Consortium for South-eastern Healthcare Quality (US non-profit; unpaid position). The BMJ policy on financial interests is here: https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf
Comment on
-
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.BMJ. 2020 Apr 29;369:m1186. doi: 10.1136/bmj.m1186. BMJ. 2020. PMID: 32349963 Free PMC article.
Similar articles
-
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.Lancet Diabetes Endocrinol. 2020 Jan;8(1):27-35. doi: 10.1016/S2213-8587(19)30384-5. Lancet Diabetes Endocrinol. 2020. PMID: 31862149
-
Safety concerns of sodium-glucose co-transporter-2 inhibitors in type 1 diabetes: A real-world study from the perspective of the Food and Drug Administration Adverse Event Reporting System.Diabetes Obes Metab. 2020 Nov;22(11):2204-2206. doi: 10.1111/dom.14138. Epub 2020 Aug 7. Diabetes Obes Metab. 2020. PMID: 32633000 No abstract available.
-
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?Diabetes Metab Syndr. 2020 Jul-Aug;14(4):347. doi: 10.1016/j.dsx.2020.04.010. Epub 2020 Apr 11. Diabetes Metab Syndr. 2020. PMID: 32305776 No abstract available.
-
SGLT2 inhibitors: molecular design and potential differences in effect.Kidney Int Suppl. 2011 Mar;(120):S14-9. doi: 10.1038/ki.2010.511. Kidney Int Suppl. 2011. PMID: 21358697 Review.
-
Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics.Curr Top Med Chem. 2011;11(12):1476-512. doi: 10.2174/156802611795860915. Curr Top Med Chem. 2011. PMID: 21510836 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
